Will Gleevec, Sprycel researchers get a call from Stockholm?

Scientists who worked on the targeted leukemia drugs Gleevec and Sprycel may be in line for the Nobel Prize this year, a prize-prediction expert says. The drugs, sold by Novartis ($NVS) and Bristol-Myers Squibb ($BMY) respectively, represent "a fundamental discovery in medicine...with a fantastic result which is often referred to in terms like 'magic bullet'," analyst David Pendlebury tells Reuters. "It has really given a new paradigm for the treatment of cancer." Report

Suggested Articles

The FDA is bracing for drug and medical supply shortages in the U.S. as the COVID-19 outbreak from China continues to spread globally.

Astellas and Seattle Genetics are out with Padcev-Keytruda combo data that may be good enough to snag an expedited regulatory review, analysts say.

Distributors had offered billions of dollars to wrap up opioid litigation, but that effort has suffered a major setback, WSJ reports.